Fresenius Kabi Succeeds In Canadian Adalimumab Tussle
Court Order Provides For Immediate Marketing Authorization
Fresenius Kabi has been forced to wait to gain a Notice of Compliance, effectively a marketing authorization, for its Idacio (adalimumab) biosimilar to Humira in Canada, in light of the Minister of Health’s interpretation of regulatory language. However, a Federal Court has now found that earlier decisions by the Ministry barring approval were unreasonable.
You may also be interested in...
Sandoz has confirmed the launch of its Hyrimoz biosimilar rival to Humira in Canada, with other biosimilars firms having also set their sights on a mid-February launch.
In the month ahead, Amarin is likely to reveal the latest on its plans to petition the US Supreme Court over generic versions of Vascepa, while biosimilar competition to Humira is set to arrive and the bulk of fourth-quarter and year-end financial results will emerge.
Fresenius Kabi insists there is a “business plan behind everything” as it divulged a higher cost savings goal for the end of next year, following a fruitful 2023. But queries over margins led the company to stress that it was combatting a variety of uncertainties, especially in China and for its burgeoning biosimilars unit.